MetLife Investment Management’s Corbus Pharmaceuticals CRBP Stock Holding History

MetLife Investment Management’s Portfolio CRBP Stock Details CRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-5,951	Closed	-$70.2K	–	2792
2024 Q4	$70.2K	Hold	5,951	–	–	﹤0.01%	2709
2024 Q3	$123K	Buy	+5,951	New	+$305K	﹤0.01%	2544
2020 Q3	–	Sell	-1,038	Closed	-$261K	–	2306
2020 Q2	$261K	Hold	1,038	–	–	﹤0.01%	1741
2020 Q1	$163K	Buy	1,038 +262	+34%	+$44.3K	﹤0.01%	1805
2019 Q4	$127K	Hold	776	–	–	﹤0.01%	2204
2019 Q3	$113K	Sell	776 -459	-37%	-$80K	﹤0.01%	2269
2019 Q2	$257K	Buy	1,235 +465	+60%	+$99.6K	﹤0.01%	1886
2019 Q1	$160K	Hold	770	–	–	﹤0.01%	2094
2018 Q4	$135K	Hold	770	–	–	﹤0.01%	2140
2018 Q3	$174K	Hold	770	–	–	﹤0.01%	2163
2018 Q2	$117K	Hold	770	–	–	﹤0.01%	2149
2018 Q1	$141K	Hold	770	–	–	﹤0.01%	2074
2017 Q4	$164K	Buy	+770	New	+$165K	﹤0.01%	2024

Other funds holding CRBP

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

EAM

Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

MetLife Investment Management's CRBP Position: Q1 2025 in Review

MetLife Investment Management sold out of Corbus Pharmaceuticals (CRBP) in Q1 2025, closing a stake of 5,951 shares — an estimated $70.2K sold.

MetLife Investment Management first reported a position in CRBP in Q4 2017 and held it in 13 quarters. The position peaked at $261K in Q2 2020. 86 funds tracked by Wall St. Rank hold CRBP as of Q1 2025.

MetLife Investment Management reported no remaining Corbus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
MetLife Investment Management sold 5,951 Corbus Pharmaceuticals shares in Q1 2025, an estimated $70.2K.
MetLife Investment Management first reported a position in Corbus Pharmaceuticals in Q4 2017 and held it in 13 quarters.
MetLife Investment Management's Corbus Pharmaceuticals position peaked at $261K in Q2 2020.
86 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q1 2025.

Based on MetLife Investment Management's 13F filing for Q1 2025, filed 14 May 2025.